Dishman Pharma acquires French contract research firm Creapharm Parenterals
17 Jan 2012
Ahmedabad-based Dishman Pharmaceuticals and Chemicals Ltd today said that it has acquired Creapharm Parenterals, the contract research and manufacturing firm of France-based Creapharm Group.
The acquisition was carried out through its Switzerland-based subsidiary Carbogen Amcis AG. Financial terms of deal were not disclosed.
''As part of this acquisition, Creapharm Parenterals, a contract development and manufacturing firm, has changed its name to Carbogen Amics SAS, said Dishman Pharmaceuticals in a filing to the Bombay Stock Exchange.
The acquisition will extend Carbogen Amics development and manufacturing services by adding complementary formulation and lyophilisation services and sterile GMP capabilities for the fast supply of drug products, including highly potents, for pre-clinical studies and clinical Phase I, II & III trials.
Creapharm Parenterals has more than 10 years of expertise in the supply of Investigational Medicinal Products, with more than 300 batches and 145 clinical batches produced since 2000. The company employs 16 specialists and operates a GMP manufacturing site in Riom, France.
Through this acquisition, Carbogen Amics has added formulation of new products for injectable, liquid and semi-solid pharmaceutical forms, including optimization of existing formulation and development and optimization of lyophilization cycles.
It will also add aseptic process validation, GMP capabilities for the development of injectables in liquid or freeze-dried forms and aseptic filling in vials, syringes, cartridges and infusion bags.
"This exciting transaction further strengthens Carbogen Amics' service offerings, enabling us to provide our customers with a complete and reliable manufacturing solution from process development to the supply of pharmaceutical substances and formulated products," said Mark Griffiths, CEO of Carbogen Amics.
"We believe that the combined capabilities and services of our two companies present a one-stop solution to pharmaceutical, biotech and virtual pharmaceutical companies looking for a single reliable partner that can provide API and drug product development for preclinical and clinical studies," said Maxime Laugier, development and projects director at Creapharm Parenterals.
